NeoGenomics price target raised to $20 from $14 at Cowen

Cowen analyst Dan Brennan raised the firm’s price target on NeoGenomics to $20 from $14 and keeps an Outperform rating on the shares. The analyst said after its earnings beat, management set the tone for further operational improvements, a competitive NGS panel coming 1Q, investment in RaDaR, and solid cost control.